Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
336.23
-14.80 (-4.22%)
Feb 21, 2025, 4:00 PM EST - Market closed
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees as of December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
$204,290
Profits / Employee
-$1,379,441
Market Cap
7.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 376 | 284 | 308.70% |
Dec 31, 2022 | 92 | 21 | 29.58% |
Dec 31, 2021 | 71 | 29 | 69.05% |
Dec 31, 2020 | 42 | 13 | 44.83% |
Dec 31, 2019 | 29 | 12 | 70.59% |
Dec 31, 2018 | 17 | 9 | 112.50% |
Dec 31, 2017 | 8 | 0 | - |
Dec 31, 2016 | 8 | -2 | -20.00% |
Dec 31, 2015 | 10 | -100 | -90.91% |
Dec 31, 2014 | 110 | -24 | -17.91% |
Dec 31, 2013 | 134 | 10 | 8.06% |
Dec 31, 2012 | 124 | 2 | 1.64% |
Dec 31, 2011 | 122 | 10 | 8.93% |
Dec 31, 2010 | 112 | -15 | -11.81% |
Dec 31, 2009 | 127 | -2 | -1.55% |
Dec 31, 2008 | 129 | -46 | -26.29% |
Dec 31, 2007 | 175 | 29 | 19.86% |
Dec 31, 2006 | 146 | 28 | 23.73% |
Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MDGL News
- 1 day ago - Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 10 days ago - Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 - GlobeNewsWire
- 23 days ago - MoneyShow's Best Investment Ideas For 2025: Part 7 - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
- 5 weeks ago - Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra - GlobeNewsWire
- 6 weeks ago - Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion - Seeking Alpha
- 6 weeks ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 7 weeks ago - Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire